Page 114 - HIVMED_v21_i1.indb
P. 114

Page 23 of 34  Guideline


              BOX 30: Recommendations for employees who are hiring people who use drugs. 124
               1. Pay attention to recruitment not only for peers but also for the staff managing peers. It is a good practice to discuss in advance with the team, involving peers and managers,
                about the desired profile and skills of new staff. Involve peers in all steps of the recruitment process.
               2. Offer diverse work-engagement levels like part-time, ad hoc activities or volunteering. Not everyone will be ready or willing to work full-time or in specific outreach
                functions. Offering different levels of engagement with work creates opportunities for people who use drugs to progress through the organisation whilst respecting their
                possibilities and needs at a given moment.
               3. Promote a harm reduction approach to drug use of staff. Develop non-prohibitionist regulations at the workplace and focus on job performance instead of on drug use. What
                matters is that staff needs to be fit for work and must protect the organisation’s image. They must be accountable for their performance, regardless of their eventual drug use.
               4. Foster a supportive work environment. Be appreciative and promote trust-building. Provide good work conditions and support workers’ needs and self-care. Be flexible with
                working hours when staff needs to attend OST or HIV/HCV/other treatment. Also, be understanding of performance problems caused by side-effects of medication, for instance.
               5. Build and sustain boundaries. This implies not only being transparent about rules and how they are applied for everyone but also help to recognise, build and sustain
                boundaries to help protect staff from emotional burden.
               6. Promote diversity and respect within the team. Invest in team care: ensure excellent communication, team-building and promote an environment of trust amongst
                colleagues. Foster the building of a diverse team and promote respect for this diversity within the team and the organisation.
               7. Promote meaningful involvement of staff members who use drugs at all levels, not only on service delivery. Include staff in planning, evaluating and policy decision making.
                This may mean helping to prepare staff on how to give feedback, as some might have internalised stigma, which can create additional difficulties in sharing ideas.
              OST, opioid substitution therapy; HCV, hepatitis C virus.
              5. Acknowledgements                                   Ethical consideration

              Additional inputs received from Lize Weich, Tanya Venter,   This article followed all ethical standards for research without
              Johannes Hugo, Urvisha Bhoora, Magriet Spies, Rafaela   direct contact with human or animal subjects.
              Rigoni, Cara O’Conner, Julia Samuelson, Viriginia
              Macdonald, Michelle Rodolph, Shona Dalal, Nurain Tisaker   Funding information
              and Shaheema Allie. Regional harm reduction case studies
              developed by Kunal Naik (PILS, Mauritius) and Bernice   No specific grant was received from any funding
              Apondi (VOCAL, Kenya).                                agency in the public, commercial or non-for-project
                                                                    sectors.
              Inputs  from  the guideline  development  workshop  held  in
              August 2019 are also included. Participants of the workshop   Data availability statement
              included: Leora Casey, Andrew Gray, Harry Hausler, Signe
              Rotberga, Muhangwi Mulaudzi, Lauren Jankelowitz, Annette   Data sharing is not applicable to this article as no new data
              Verster, Busisiwe Msimanga-Radebe, Nontsikelelo Mpulo,   were created or analysed in this study.
              Zukiswa Ngobo, Mpho Maraisane, Rogerio Phili, Kgalabi
              Ngako,  Maria  Sibanyoni,  Yolanda  Ndimande,  Valencia   Disclaimer
              Malaza, Johannes Hugo, Urvisha Bhoora and Cara O’Conner.
                                                                    Specific recommendations provided here are intended
              We extend our thanks to the external reviewers, including   only  as a guide to clinical management,  based on expert
              Julie Bruneau,  Annette Verster, Kunal Naik, Nkereuwem   consensus and best current evidence. Treatment decisions
              William Ebiti and Ali Feizzadeh.                      for patients should be made by their responsible clinicians,
                                                                    with due consideration for individual circumstances. The
              Competing interests                                   most current version of this document should always be
              The authors confirm that no competing interests exist.  consulted.

                                                                    The views and opinions expressed in this article are those of
              Authors’ contributions                                the authors and do not necessarily reflect the official position
              All authors contributed equally to this work.         of any affiliated agency of the authors.
























                                           http://www.sajhivmed.org.za 106  Open Access
   109   110   111   112   113   114   115   116   117   118   119